Top
Main

All outcomes

Feedback
Home
Show Outline
Top   Main   All Outcomes
Home   COVID-19 treatment studies for Diet  COVID-19 treatment studies for Diet  C19 studies: Diet  Diet   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
Loading...
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc
Supplementary Data — Diet for COVID-19: real-time meta analysis of 18 studies
Covid Analysis, October 3, 2022, DRAFT
https://c19early.com/dtmeta.html
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Mahto 20% 0.80 [0.49-1.21] IgG+ 23/206 70/483 Improvement, RR [CI] Treatment Control Naushin 40% 0.60 [0.50-0.71] seropositive n/a n/a Kim 72% 0.28 [0.10-0.82] m/s case 41 (n) 527 (n) Kim 59% 0.41 [0.16-0.99] m/s case 46 (n) 522 (n) Kim 19% 0.81 [0.56-1.15] cases 41 (n) 527 (n) Kim 23% 0.77 [0.55-1.08] cases 46 (n) 522 (n) Merino 41% 0.59 [0.47-0.74] severe case 148,142 (n) 148,143 (n) Merino 18% 0.82 [0.78-0.86] cases 148,142 (n) 148,143 (n) Merino 9% 0.91 [0.88-0.94] cases 148,142 (n) 148,143 (n) Moludi 92% 0.08 [0.05-0.19] cases n/a n/a Ahmadi -3% 1.03 [0.77-1.39] death 185/206,286 62/75,264 Nguyen 15% 0.85 [0.75-0.96] symp. case 345/1,054 433/1,082 Yamamoto 66% 0.34 [0.13-0.85] cases 4/20 19/32 MagaƱa 53% 0.47 [0.22-0.99] death 58 (n) 31 (n) Jagielski 82% 0.18 [0.04-0.65] cases 4/40 9/20 Perez-Araluce 78% 0.22 [0.03-1.77] severe case 1/1,103 10/3,300 Perez-Araluce 15% 0.85 [0.62-1.15] symp. case 52/1,103 214/3,300 Perez-Araluce 20% 0.80 [0.60-1.07] cases 58/1,103 248/3,300 Firoozi 65% 0.35 [0.28-0.43] cases case control per unit E-DII change Hou 72% 0.28 [0.04-1.95] severe case 1/22 78/487 Hou 11% 0.89 [0.58-1.36] m/s case 11/22 273/487 Hou 74% 0.26 [0.10-0.67] severe case 0/9 47/127 Hou 35% 0.65 [0.36-1.18] m/s case 5/9 108/127 Zargarzadeh 77% 0.23 [0.11-0.50] severe case 89 (n) 80 (n) Yue 19% 0.81 [0.69-0.94] cases n/a n/a Yue 21% 0.79 [0.67-0.94] cases n/a n/a Yue 29% 0.71 [0.61-0.83] cases n/a n/a Yue 12% 0.88 [0.76-1.02] cases n/a n/a Zhou 16% 0.84 [0.78-0.91] cases 1,321/10,254 1,935/10,253 Ebrahimzadeh 69% 0.31 [0.14-0.68] severe case n/a n/a Ebrahimzadeh 56% 0.44 [0.18-1.06] hosp. n/a n/a Ebrahimzadeh 68% 0.32 [0.15-0.68] no recov. n/a n/a Tadbir Vajargah 67% 0.33 [0.16-0.69] severe case 83 (n) 83 (n) Tadbir Vajargah 72% 0.28 [0.14-0.58] severe case 83 (n) 83 (n) Tadbir Vajargah 75% 0.25 [0.12-0.53] severe case 83 (n) 83 (n) diet COVID-19 outcomes c19early.com/dt Oct 2022 Favors healthy diet Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit